Citations (42)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Jean-Yves Reginster & Audrey Neuprez. (2010) Strontium ranelate: a look back at its use for osteoporosis. Expert Opinion on Pharmacotherapy 11:17, pages 2915-2927.
Read now
Read now
Articles from other publishers (41)
A. V. Krivova, V. P. Zakharov & A. N. Sharov. (2022) Role of zoledronic acid in treatment of osteoporosis and prevention of fractures. Meditsinskiy sovet = Medical Council:21-2, pages 102-109.
Crossref
Crossref
Naoki Okubo, Shigeyuki Matsui, Toshio Matsumoto, Toshitsugu Sugimoto, Takayuki Hosoi, Taisuke Osakabe, Ko Watanabe, Hideo Takami, Masataka Shiraki & Toshitaka Nakamura. (2020) Relationship Between Bone Mineral Density and Risk of Vertebral Fractures with Denosumab Treatment in Japanese Postmenopausal Women and Men with Osteoporosis. Calcified Tissue International 107:6, pages 559-566.
Crossref
Crossref
Łukasz John, Marta Podgórska, Jean-Marie Nedelec, Łucja Cwynar-Zając & Piotr Dzięgiel. (2016) Strontium-doped organic-inorganic hybrids towards three-dimensional scaffolds for osteogenic cells. Materials Science and Engineering: C 68, pages 117-127.
Crossref
Crossref
A. Catalano, N. Morabito, A. Di Stefano, E. Morini, G. Basile, B. Faraci, S. Loddo, R. Ientile & A. Lasco. (2015) Vitamin D and bone mineral density changes in postmenopausal women treated with strontium ranelate. Journal of Endocrinological Investigation 38:8, pages 859-863.
Crossref
Crossref
J.Y. Reginster, A. Neuprez, N. Dardenne, C. Beaudart, P. Emonts & O. Bruyere. (2014) Efficacy and safety of currently marketed anti-osteoporosis medications. Best Practice & Research Clinical Endocrinology & Metabolism 28:6, pages 809-834.
Crossref
Crossref
Olivier Bruyère & Jean-Yves Reginster. (2014) Monitoring of osteoporosis therapy. Best Practice & Research Clinical Endocrinology & Metabolism 28:6, pages 835-841.
Crossref
Crossref
Lola S. Abboskhujaeva, Saydiganikhodja I. Ismailov & Nodira M. Alikhanova. (2014) Efficacy of Strontium Ranelate in Combination with a D-Hormone Analog for the Treatment of Postmenopausal Osteoporosis. Drugs in R&D 14:4, pages 315-324.
Crossref
Crossref
M. Hiligsmann, W. Ben Sedrine, O. Bruyère & J.-Y. Reginster. (2013) Cost-effectiveness of strontium ranelate in the treatment of male osteoporosis. Osteoporosis International 24:8, pages 2291-2300.
Crossref
Crossref
Luisella Cianferotti, Federica D’Asta & Maria Luisa Brandi. (2013) A review on strontium ranelate long-term antifracture efficacy in the treatment of postmenopausal osteoporosis. Therapeutic Advances in Musculoskeletal Disease 5:3, pages 127-139.
Crossref
Crossref
Gregory R. Wohl, David R. Chettle, Ana Pejović-Milić, Cheryl Druchok, Colin E. Webber, Jonathan D. Adachi & Karen A. Beattie. (2013) Accumulation of bone strontium measured by in vivo XRF in rats supplemented with strontium citrate and strontium ranelate. Bone 52:1, pages 63-69.
Crossref
Crossref
J. A. Kanis, E. V. McCloskey, H. Johansson, C. Cooper, R. Rizzoli & J.-Y. Reginster. (2012) European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporosis International 24:1, pages 23-57.
Crossref
Crossref
Olivier Bruyère, Johann Detilleux, Arkadi Chines & Jean-Yves Reginster. (2012) Relationships Between Changes in Bone Mineral Density or Bone Turnover Markers and Vertebral Fracture Incidence in Patients Treated with Bazedoxifene. Calcified Tissue International 91:4, pages 244-249.
Crossref
Crossref
Richard M Jacques, Steven Boonen, Felicia Cosman, Ian R Reid, Douglas C Bauer, Dennis M Black & Richard Eastell. (2012) Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once‐yearly zoledronic acid 5 mg: The HORIZON‐Pivotal Fracture Trial (PFT). Journal of Bone and Mineral Research 27:8, pages 1627-1634.
Crossref
Crossref
Matthew Austin, Yu‐Ching Yang, Eric Vittinghoff, Silvano Adami, Steven Boonen, Douglas C Bauer, Gerolamo Bianchi, Michael A Bolognese, Claus Christiansen, Richard Eastell, Andreas Grauer, Federico Hawkins, David L Kendler, Beatriz Oliveri, Michael R McClung, Ian R Reid, Ethel S Siris, Jose Zanchetta, Cristiano AF Zerbini, Cesar Libanati & Steven R Cummings. (2012) Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures. Journal of Bone and Mineral Research 27:3, pages 687-693.
Crossref
Crossref
Li-Juan Chen, Lu-Ying Tang, Jian-Rong He, Yi Su, Yu-Ling Cen, Dan-Dan Yu, Bang-Hua Wu, Ying Lin, Wei-Qing Chen, Er-Wei Song & Ze-Fang Ren. (2012) Urinary strontium and the risk of breast cancer: A case-control study in Guangzhou, China. Environmental Research 112, pages 212-217.
Crossref
Crossref
Wei Song, Qiguang Wang, Changxiu Wan, Tong Shi, David Markel, Ralph Blaiser & Weiping Ren. (2011) A novel alkali metals/strontium co-substituted calcium polyphosphate scaffolds in bone tissue engineering. Journal of Biomedical Materials Research Part B: Applied Biomaterials 98B:2, pages 255-262.
Crossref
Crossref
P. J. Marie, D. Felsenberg & M. L. Brandi. (2010) How strontium ranelate, via opposite effects on bone resorption and formation, prevents osteoporosis. Osteoporosis International 22:6, pages 1659-1667.
Crossref
Crossref
Bernard Cortet. (2010) Use of Strontium as a Treatment Method for Osteoporosis. Current Osteoporosis Reports 9:1, pages 25-30.
Crossref
Crossref
Bernard Cortet. (2011) Treatment of Postmenopausal Osteoporosis: Focus on Strontium Ranelate. Clinical Medicine Insights: Women's Health 4, pages CMWH.S5149.
Crossref
Crossref
Julien Paccou, Cyrille B. Confavreux, Claire David, Ariane Leboime, Nadia Mehsen & Bernard Cortet. (2010) Stabilized severe osteoporosis: should the treatment be stopped?. Joint Bone Spine 77, pages S120-S127.
Crossref
Crossref
&NA;. (2010) Strontium ranelate: a guide to its use in postmenopausal osteoporosis. Drugs & Therapy Perspectives 26:10, pages 6-10.
Crossref
Crossref
Julien Paccou, Cyrille B. Confavreux, Claire David, Ariane Leboime, Nadia Mehsen & Bernard Cortet. (2010) Faut-il interrompre le traitement d’une ostéoporose sévère qui est stabilisée ?. Revue du Rhumatisme 77, pages S60-S67.
Crossref
Crossref
Jean-Yves ReginsterMickaël Hiligsmann & Olivier Bruyere. (2010) Strontium ranelate: long-term efficacy against vertebral, nonvertebral and hip fractures in patients with postmenopausal osteoporosis. Therapeutic Advances in Musculoskeletal Disease 2:3, pages 133-143.
Crossref
Crossref
C. Cooper. (2010) Osteoporosis: disease severity and consequent fracture management. Osteoporosis International 21:S2, pages 425-429.
Crossref
Crossref
R. Rizzoli. (2010) Microarchitecture in focus. Osteoporosis International 21:S2, pages 403-406.
Crossref
Crossref
O. Bruyere, J. Collette & J.-Y. Reginster. (2010) The effects of strontium ranelate on biochemical markers of bone turnover and their relationship with bone mineral density: reply to Stepan et al.. Osteoporosis International 21:6, pages 1039-1040.
Crossref
Crossref
O. Bruyère, J. Collette, R. Rizzoli, C. Decock, S. Ortolani, C. Cormier, J. Detilleux & J.-Y. Reginster. (2009) Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. Osteoporosis International 21:6, pages 1031-1036.
Crossref
Crossref
Emma D. Deeks & Sohita Dhillon. (2010) Strontium Ranelate. Drugs 70:6, pages 733-759.
Crossref
Crossref
Ego Seeman, Steven Boonen, Frederik Borgström, Bruno Vellas, Jean-Pierre Aquino, Jutta Semler, Claude-Laurent Benhamou, Jean-Marc Kaufman & Jean-Yves Reginster. (2010) Five years treatment with strontium ranelate reduces vertebral and nonvertebral fractures and increases the number and quality of remaining life-years in women over 80 years of age. Bone 46:4, pages 1038-1042.
Crossref
Crossref
Patricia Belissa-Chatelain, Isabelle Dupin-Roger, Fabienne Cournarie & Yannis Tsouderos. (2009) Re: “Effect of long-term treatment with strontium ranelate on bone strontium content” by Bärenholdt et al. (Bone, 2009). Bone 45:5, pages 1024-1025.
Crossref
Crossref
Olivier Bruyere, Alfredo Roces Varela, Silvio Adami, Johann Detilleux, Véronique Rabenda, Mickael Hiligsmann & Jean-Yves Reginster. (2009) Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women. European Journal of Epidemiology 24:11, pages 707-712.
Crossref
Crossref
N. A. T. Hamdy. (2009) Strontium ranelate improves bone microarchitecture in osteoporosis. Rheumatology 48:suppl 4, pages iv9-iv13.
Crossref
Crossref
P. J. Meunier, C. Roux, S. Ortolani, M. Diaz-Curiel, J. Compston, P. Marquis, C. Cormier, G. Isaia, J. Badurski, J. D. Wark, J. Collette & J. Y. Reginster. (2009) Effects of long-term strontium ranelate treatment on vertebral fracture risk in postmenopausal women with osteoporosis. Osteoporosis International 20:10, pages 1663-1673.
Crossref
Crossref
Jian-Min Liu, Annie Wai-chee Kung, Chan Siew Pheng, Han-Min Zhu, Zhen-Lin Zhang, Yi-Yong Wu, Ling Xu, Xun-Wu Meng, Min-Li Huang, Leung Ping Chung, Nik Hazlina Nik Hussain, Seri Suniza Sufian & Jia-Lun Chen. (2009) Efficacy and safety of 2 g/day of strontium ranelate in Asian women with postmenopausal osteoporosis. Bone 45:3, pages 460-465.
Crossref
Crossref
Jean-Yves Reginster, Rita Deroisy, Audrey Neuprez, Mickaël Hiligsmann, Brigitte Zegels & Olivier Bruyere. (2009) Strontium ranelate: New data on fracture prevention and mechanisms of action. Current Osteoporosis Reports 7:3, pages 96-102.
Crossref
Crossref
D. L. Kendler, J. D. Adachi, R. G. Josse & D. O. Slosman. (2009) Monitoring strontium ranelate therapy in patients with osteoporosis. Osteoporosis International 20:7, pages 1101-1106.
Crossref
Crossref
Carlina V. Albanese & Roberto PassarielloMaria Luisa Brandi. 2009. Osteoporosi e malattie metaboliche dell’osso. Osteoporosi e malattie metaboliche dell’osso
515
520
.
Audrey Neuprez, Mickaël Hiligsmann, Sophie Scholtissen, Olivier Bruyere & Jean-Yves Reginster. (2008) Strontium ranelate: The first agent of a new therapeutic class in osteoporosis. Advances in Therapy 25:12, pages 1235-1256.
Crossref
Crossref
Sebastian Seitz, F. Timo Beil, Florian Barvencik, Christoph von Domarus, Johannes M. Rueger & Michael Amling. (2008) Postoperative Protocol in the Prevention of Fragility Fractures in Patients with Osteoporosis-Related Fractures. European Journal of Trauma and Emergency Surgery 34:6, pages 542-548.
Crossref
Crossref
Audrey Neuprez & Jean-Yves Reginster. (2008) Bone-forming agents in the management of osteoporosis. Best Practice & Research Clinical Endocrinology & Metabolism 22:5, pages 869-883.
Crossref
Crossref
Mary L Bouxsein & Pierre D Delmas. (2009) Considerations for Development of Surrogate Endpoints for Antifracture Efficacy of New Treatments in Osteoporosis: A Perspective. Journal of Bone and Mineral Research 23:8, pages 1155-1167.
Crossref
Crossref